CNS Pharmaceuticals Inc.
13F holders, Q3 2024 (September 30)14holders +4
7new positions
3sold out
$0.13avg. 13F price*
At the end of Q3 2024, 14 institutions reported holding CNS Pharmaceuticals Inc. in their 13F filings, up 4 from Q2 2024. 7 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($27K), UBS Group AG ($24K) and Virtu Financial LLC ($16K).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H300
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $49K |
| Exits | 3 | $223K |
All 13F filers, Q2 2024 → Q3 2024: 573,469 shares bought and 141,401 shares sold, net +432,068 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Geode Capital Management, LLC | 0.00% | New | 203,180 | $27K |
| UBS Group AG | 0.00% | Add +6817.7% | 181,866 | $24K |
| Virtu Financial LLC | 0.00% | New | 122,876 | $16K |
| Goldman Sachs Group Inc. | 0.00% | New | 28,197 | $4K |
| Jane Street Group, LLC | 0.00% | New | 23,160 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +14072.2% | 16,298 | $2K |
| Aspire Private Capital, LLC | 0.00% | New | 400 | $52 |
| Bank of America Corp. | 0.00% | Add +23300.0% | 234 | $30 |
| Wells Fargo & Company | 0.00% | No change | 4 | $1 |
| Danske Bank A/S | 0.00% | New | 2 | $0 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 1 | $0 |
| Plante Moran Financial Advisors, LLC | 0.00% | No change | 1 | $0 |
| Parallel Advisors, LLC | 0.00% | No change | 1 | $0 |
| Global Retirement Partners, LLC | 0.00% | No change | 2 | $0 |
"% of holder's portfolio" is CNS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.